In an effort to determine whether pre-mNKs were responsible for the tumor growth and survival discrepancies between RAG−/− animals receiving ACT alone or RAG−/− animals receiving anti-NK1.1 antibodies in addition to ACT, we performed ACT in combination with anti-B220 therapy. The gene discussed is PTPRC; the disease is neoplasm.